Results 211 to 220 of about 18,118,892 (286)
US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes. [PDF]
J Comp Eff ResKasle A +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert review of pharmacoeconomics & outcomes research, 2021
Objectives From the demand-side perspective, the monetary value of one additional quality-adjusted life year (QALY) is estimated as willingness-to-pay per QALY (WTPQ). This study aims to summarize the methods and contexts of elicitation of willingness-to-
Ziping Ye +5 more
semanticscholar +1 more source
Objectives From the demand-side perspective, the monetary value of one additional quality-adjusted life year (QALY) is estimated as willingness-to-pay per QALY (WTPQ). This study aims to summarize the methods and contexts of elicitation of willingness-to-
Ziping Ye +5 more
semanticscholar +1 more source
Practical Neurology, 2008
Many health systems now use cost-effectiveness analysis to decide which interventions and programmes to fund. A key issue for such decision making is how to measure health outcomes from interventions to reflect changes in both health-related quality of life and life expectancy.
Yolanda, Bravo Vergel, Mark, Sculpher
openaire +3 more sources
Many health systems now use cost-effectiveness analysis to decide which interventions and programmes to fund. A key issue for such decision making is how to measure health outcomes from interventions to reflect changes in both health-related quality of life and life expectancy.
Yolanda, Bravo Vergel, Mark, Sculpher
openaire +3 more sources
The Quality-Adjusted Life Year
Valuing Health in Practice, 2019D. McCulloch
semanticscholar +2 more sources
Willingness to Pay for a Quality-adjusted Life Year
Medical Decision Making, 2000Cost-benefit analysis (CBA) provides a clear decision rule: undertake an intervention if the monetary value of its benefits exceed its costs. However, due to a reluctance to characterize health benefits in monetary terms, users of cost-utility and cost-effectiveness analyses must rely on arbitrary standards (e.g., < $50,000 per QALY) to deem a ...
R. Hirth +4 more
semanticscholar +3 more sources
Disability, Epistemic Harms, and the Quality-Adjusted Life Year
International Journal of Feminist Approaches to Bioethics, 2020:Health economists use a conceptual tool called the quality-adjusted life year (QALY) in resource allocation decisions. Despite claims that the values of disabled people are distorted by adaptive preference, I argue that their testimony is in fact more ...
Laura M. Cupples
semanticscholar +1 more source
Utilities and Quality-Adjusted Life Years
International Journal of Technology Assessment in Health Care, 1989Utilities and quality-adjusted life years (QALYs) are reviewed, with particular focus on their use in technology assessment. This article provides a broad overview and perspective on these two techniques and their interrelationship, with reference to other sources for details of implementation.
G W, Torrance, D, Feeny
openaire +2 more sources